Isturisa Continues to Lower Cortisol Levels in Phase 2 Extension Trial
Isturisa (osilodrostat) led to sustained reductions in cortisol levels in people with Cushing’s disease over nearly seven years of treatment in an extension phase of the Phase 2 LINC-2 trial. Cardiovascular symptoms were also well controlled throughout the study and no new safety signals were detected. “These data…